Orphan drugs, allopurinol and CVD, mavacamten for obstructive hypertrophic cardiomyopathy

In this podcast accompanying the October issue of DTB ( ) David Phizackerley (DTB Editor) is joined by Julian Treadwell (DTB Associate Editor). David and Julian discuss the editorial that highlights a few of the challenges associated with the introduction of an orphan medicine into clinical practice ( ). They talk about a DTB Select article that summarises a randomised clinical trial that assessed the effect of allopurinol on cardiovascular outcomes in people with ischaemic heart disease who did not have gout ( ). They finish by discussing the main article that provides an overview of the evidence for mavacamten (▼Camzyos) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults ( ). Links GP Evidence: Preventing Overdiagnosis 2025 International Conference: Please

You can listen to Orphan drugs, allopurinol and CVD, mavacamten for obstructive hypertrophic cardiomyopathy online on Radio and Podcast. Open the player on this page to stream the available audio.

Orphan drugs, allopurinol and CVD, mavacamten for obstructive hypertrophic cardiomyopathy is an episode from DTB podcast by BMJ Group.

This episode is 30:14 long.

This episode was published on Oct 1, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from DTB podcast when more episodes are available from the podcast feed.